$WTG

Wintergreen Acquisition Corp. (WTG): Entry into a Material Definitive Agreement

Wintergreen Acquisition Corp. (WTG) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 THIS PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS PROMISSORY NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THER

Original reporting
Published Sep 3, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$WTG
Neutral
medium confidence
Mentioned
$WTG
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$WTGNeutralLow
01

Why it matters

The note provides incremental runway to Sept. 30, 2026, reducing the immediate risk of liquidation tied to the prior Aug. 30, 2026 deadline. Conversion is at the payee’s option into units at $10.00 per unit upon a business combination, subject to an aggregate conversion cap.

02

Market read

This is a SPAC extension financing disclosure that can modestly improve near-term sentiment by lowering deadline risk, but the disclosed principal is small.

03

What to watch

Traders may focus less on the loan size and more on whether the SPAC has a credible target and timeline to consummate the business combination before the extended deadline.

Relevance 6/10Novelty 6/10Timing: Filed Sept. 3, 2026, supporting a trust extension to Sept. 30, 2026.

Background

The 8-K reports entry into a material definitive agreement, including a promissory note used to fund a one-month extension of the SPAC’s business-combination deadline via its trust account.

Company-level read

Ticker impact

$WTGNeutralMedium confidence
Context

Wintergreen Acquisition Corp. entered a material definitive agreement via an unsecured $184,635 promissory note to fund a one-month trust extension.

Expected impact

Near-term impact likely limited, but it can reduce “deadline risk” and modestly support sentiment around the extension window.

Evidence & confidence

The note funds a one-month extension with no interest accrual, and repayment is tied to consummating a business combination; the disclosed principal is small, suggesting limited balance-sheet stress but some reduction in liquidation probability.

Market effects

Adds another example of SPAC extension financing mechanics, but with limited scale so it is unlikely to move the broader SPAC complex.

No clear regional spillover beyond US-listed SPAC sentiment.

Minimal, as the transaction is specific to the issuer’s trust extension and private note terms.

Counterpoint

Because the note is small and carries no interest, it may signal limited financing capacity, which could be read as a weaker ability to secure larger extension or deal funding.

Key entities

  • Wintergreen Acquisition Corp.

    SPAC maker that entered the promissory note agreement to fund a one-month trust extension.

  • MACRO DREAM Holdings Limited

    Payee under the unsecured promissory note, with an option to convert into units upon a business combination.

Related articles

$ENPHMedAI 8/10

, Enphase Energy, Inc. entered into a Tax Credit Transfer Agreement with a leading corporation

Enphase Energy, Inc. (ENPH) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events On October 28, 2026 (the “Effective Date”), Enphase Energy, Inc. (the “Company”) entered into a Tax Credit Transfer Agreement (the “Agreement”) with a leading corporation (the “Purchaser”). Pursuant to the Agreement, the Company agreed to sell to the Purcha

$BHVNHighAI 9/10

A drug deal could bring Biohaven $400 million, with $350 million at closing

Biohaven (BHVN) announced FDA acceptance of its Vyglxia (troriluzole) resubmission for spinocerebellar ataxia, with a 1Q27 user fee goal date. The company secured two licensing deals: a $400M agreement with SK Biopharmaceuticals for its Kv7 ion channel platform, and a $20M upfront plus $80M milestone deal with Ono Pharmaceutical for its MoDE IgG degrader portfolio.